but have generally similar serum IGF-I levels [3, 4] . As expected, female with GH deficiency need a higher dose of GH than male to maintain normal serum IGF-I levels [5, 6] . Female with acromegaly have lower serum IGF-I levels for a given serum GH value than male, and female with acromegaly need lower doses of octreotide than male to normalize serum IGF-I levels [7] . Observations in normal subjects and patients with abnormal GH secretary states suggest that gender affects the GH secretory pattern; however, the impact of gender on the GH response to hypothalamic hormones or glucose in acromegaly remains uncertain.
Here, we report the influence of gender on GH secretion in acromegaly. We describe the relationship between serum GH and IGF-I levels. Additionally, we present our observations on the effect of gender on the GH responses to an oral glucose tolerance test (OGTT), thyrotropin releasing hormone (TRH), octreotide, and bromocriptine.
Patients and methods
Eighty-eight consecutive patients with untreated acromegaly who were admitted to the Department lower than values obtained using the standards for pituitary-derived GH. Therefore, we adjusted the serum GH concentration measured before April 2005 to the rhGH standard. Serum IGF-I concentrations were measured with an IRMA kit (Daiichi Radioisotope Laboratories). The standard deviation scores (SDS) for serum IGF-I levels were adjusted for sex and age, according to the constructed reference [9] .
Statistics
All statistical analyses were performed using Stat View R 5.0 (SAS institute Inc., USA), with statistical significance established at p<0.05. All data are expressed as median values. The Mann-Whitney test was performed to investigate the relationship between gender and basal GH and IGF-I levels, IGF-I SDS and the response rate of GH to each loading test. Fisher's exact probability test was performed to investigate the gender difference in the prevalence of responders for the TRH and bromocriptine loading tests.
results
Serum GH, IGF-I levels and their ratio in patients with acromegaly were shown in Table 1 , Fig. 1 and Fig. 2 . The basal serum GH levels ranged from 1.1 to 42.6 ng/mL (median of 6.1 ng/mL) in 27 male patients, and from 1.0 to 133.5 ng/mL (median of 8.7 ng/mL) in 47 female patients. There were no significant differences in basal GH levels between male and female patients. The serum IGF-I levels ranged from 325 to 1450 ng/mL (median of 769 ng/mL) in male, and from 306 to 1200 ng/mL (median of 679 ng/mL) in female. The IGF-I levels in female were significantly lower than those in male (p<0.02). The IGF-I SDS ranged from 3.0 to 14.0 (median of 9.2) in male, and from 3.7 to 11.7 (median of 7.3) in female. The IGF-I SDS in female were significantly lower than those in male (p<0.02). The IGF-I/GH ratios ranged from 25.8 to 378.5 (median of 141.5) in male, and from 6.7 to 489.1 (median of 79.6) in female. The IGF-I/GH ratios in female were significantly lower than those in male (p<0.05). The IGF-I SDS/GH ratios ranged from 0.27 to 3.88 (median of 1.49) in male, and from 0.05 to 6.70 (median of 0.82) in female. The IGF-I SDS/GH ratios in female were significantly lower than those in male (p<0.05). The IGF-I SDS were plotted as a function of the corresponding serum GH concentration in Fig. 3 . Based on the linear regression analyof Medicine, Institute of Clinical Endocrinology, at Tokyo Women's Medical University Hospital between 1999 and 2006 were included in this study. Patients with concomitant hyperprolactinemia (PRL >25 ng/ mL) were excluded due to the higher incidence of hypogonadism. Patients with overt hypogonadotropic hypogonadism (diagnosed by an LHRH loading test) were also excluded. As a result, a retrospective chart analysis was performed on 74 patients (M/ F 27/47, age range M:22-72, F:25-86). The diagnosis of acromegaly was based on clinical signs and lack of suppression of GH to less than 1 ng/mL after a 75 g OGTT and/or elevated serum IGF-I levels. Pituitary adenomas were detected by magnetic resonance imaging in all patients. None of the 47 female received either estrogen alone or in combination with progesterone. The basal serum GH level was an average of three samples taken on different days.
A 75 g OGTT was performed in 67 of 74 patients, as the remaining seven patients had overt diabetes mellitus. A TRH loading test was performed in 73 patients. A 200 μg dose of TRH was injected as an intravenous bolus and blood samples were obtained for GH measurements at 0, 30, and 60 minutes after administration. A 200% increase in serum GH over basal levels was regarded as a paradoxical response. Following the subcutaneous injection of 50 μg octreotide or the oral administration of 2.5 mg bromocriptine, serum GH was measured every two hours until eight hours after administration. The octreotide administration test and bromocriptine loading test were performed in 50 and 56 patients, respectively, all of whom were predicted to require adjuvant therapy. A 50% decrease in the lowest GH levels over basal GH levels was regarded as positive suppression for octreotide or a paradoxical response for bromocriptine. All of these tests were initiated between the hours of 0800 and 0900 in the morning.
Assays for GH and IGF-I
Through August 2005, the serum GH concentrations were measured using a immunoradiometric assay (IRMA) kit (Daiichi Radioisotope Laboratories, Tokyo, Japan). An immunoenzymometric assay (IEMA) kit (Tosoh Co. Ltd., Tokyo, Japan) was used from September 2005. From April 2005, serum GH concentrations were measured using a recombinant human GH (rhGH) standard [8] . GH values measured using the rhGH standard were approximately 60% Gender differences in acromegaly 
Discussion
In this study, we analyzed gender differences in the basal GH and IGF-I levels and the GH response to dynamic tests in patients with active acromegaly. We found that serum IGF-I levels in female were lower than those in male, although the median basal GH levels did not differ between male and female. As a consequence, IGF-I levels for a given serum GH level (IGF-I/GH ratio) in female were significantly lower than those in male in patients with acromegaly. Several previous studies have indicated that there is sis, IGF-I SDS plateaued when serum GH was above 20 ng/mL in male and 30 ng/mL in female. In order to confirm the influence of gender on IGF-I SDS, we analyzed gender and GH by multiple regression analysis with the stepwise method. Overall formula for IGF-I SDS was calculated as fellows. IGF-I SDS=6.5821-0.9611Gender{Female:1, Male:-1}(p=0.005)+1.8723 logGH(p=0.002). The regression factor was calculated as fellows, with 0.2255 for R square and 0.2033 for adjusted R square. Therefore, gender and GH can accout for IGF SDS by up to 20.3%.
As we observed a significant gender difference in the IGF-I/GH ratio, the IGF-I/GH ratio was evaluated with the subjects stratified for age to assess for a sex steroid dependent effect. We divided the patients into the following two groups based on age: below or equal to 50 yrs (n=35, M/F 18/17); and above 50 yrs (n=39, M/F 9/30), considerning the age of natural menopause in Japanese women. No women with acromegaly measured basal body temperature. Twelve out of 17 women below equal 50 years old and two out of 30 women above 50 years old had normal menstrual cycle. The median basal serum GH levels were not different between male and female in both age groups (age ≤ 50; 7.0 vs. 8.7 ng/mL and age > 50; 5.4 vs. 7.8 ng/mL). The IGF-I levels in female were significantly lower than those in male in the age ≤ 50 group (650 vs.1002 ng/mL, p<0.05). In the age > 50 group, there were no gender differences in the IGF-I levels. The values of IGF-I SDS in female were tend to be lower than those in male (7.1 vs. 10.0 ng/mL) in the age ≤ 50 group, but in the age > 50 group, the values were not different between male and female. The IGF-I/GH ratios in female were significantly lower than those in male in the age ≤ 50 (59.8 vs. 142.9, p<0.05). In the hyperprolactinemia and overt hypogonadotropic hypogonadism was similar to those in postmenopausal women. These findings presumably reflected the interaction between sex steroids and the GH/IGF-I axis.
Whether the GH response to a glucose load is dependent on gender has been investigated [18, 19, 20, 21] . Serum GH concentrations are lower in male than in female both at baseline and at the post glucose GH nadir in patients with acromegaly as well as in normal subjects [19, 20, 21] . Consequently, there are no gender differences in the percentage of GH suppression after a glucose load either in normal subjects or in those with acromegaly and a residual tumor after transsphenoidal surgery [19, 22] . In agreement with these previous data, the nadir GH/basal GH ratios in the present study were not significantly different between male and female with acromegaly. In contrast, Colao et al. reported a significantly higher GH suppression rate after a glucose load in male patients over 40 years of age compared with age-matched female patients [18] . In the preceding study, GH levels after an OGTT were suppressed below 50% of baseline in 40% of the patients while the rate was only 4.5% (3/67) in our patients. It is difficult to explain these differences; however, a difference in GH sensitivity to glucose suppression between the two groups may explain the results.
In acromegaly, a paradoxical response of GH following administration of TRH or bromocriptine is observed in about 60% and 30-65% of the patients, respectively [23] . These dynamic tests are used as an ancillary diagnostic test for acromegaly. The shortacting octreotide test has been widely used to predict the treatment effects for somatostatin analogues, though some do not support this. Gender differences in the suppression rate of GH by bromocriptine and octreotide are not well described. Engstrom et al. reported that male and female with acromegaly had a similar response to short-acting octreotide in terms of GH suppression, but male need higher doses of octreotide than female to normalize IGF-I [7] . The authors presumed that the influence of gender was not at the level of the pituitary but rather resulted from an increased response to GH in the periphery in male. In this study, gender differences were not observed either in the prevalence of responders or in the percentage change in GH in the responders to dynamic tests utilizing TRH, bromocriptine, or octreotide.
In conclusion, the IGF-I/GH ratio in female was a sexual dimorphism in the regulation of GH secretion pattern in healthy subjects [10, 11] . Jaffe et al. reported that female had more GH pulses and that the interpulse GH levels in female were twice as high as in male. The daily total GH secretion, however, was similar between male and female in this study [12] . Moreover, the administration of rhIGF-I had less effect on the GH response to GHRH in female than in male. The mean daily production of GH is approximately three times greater in female than in male to maintain equivalent serum IGF-I levels [3] , suggesting that in healthy subjects, a relative GH resistance is observed in female compared with male. Our findings suggest that the interaction between the GH/IGF-I axis and gender is preserved even in the state of GH excess caused by a GH producing tumor. Concerning the relationship between GH and IGF-I in acromegaly, the basal IGF-I level but not the GH was lower in female than in male with acromegaly [13, 14] . Parkinson et al. reported that female had on average serum IGF-I levels 11.4 nmol/L lower than male with the same mean serum GH in acromegaly [13] . Consistent with these reports, we observed a lower IGF-I/GH ratio in female with acromegaly compared with male.
The biological action of sex steroids is one of the factors that modifies the relationship between GH and IGF-I. Administration of oral estrogen in healthy postmenopausal female induces a 30% decrease in serum IGF-I levels and increases pituitary GH secretion, indicating that estrogen antagonizes GH-induced hepatic IGF-I production [15] . Recently, Leung et al. described the mechanism of this phenomenon. Their in vitro study has demonstrated that estradiol inhibits GH signalling by stimulating the synthesis of SOCS-2, a suppressor of cytokine signalling [16] . In contrast, testosterone may stimulate IGF-I production as testosterone administration in males increases the serum IGF-I concentration [17] .
To assess the effect of sex steroids, we divided the subjects into two groups according to age: below or equal to 50 yrs and above 50 yrs. We observed that the IGF-I/GH ratios in female were significantly lower than those ratios in male only in patients with in the age ≤ 50 group. Our results were consistent with the data of Colao et al [18] who observed that basal IGF-I levels were significantly lower in female than in male only in their youngest group. Moreover, IGF-I/ GH ratio in excluded 14 patients with concomitant
